Skip to main content
Glama

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already signal read-only/idempotent behavior, and the description adds rich behavioral context beyond that: cascading internal lookups, graceful degradation of LEI/FIGI enrichment, ambiguous-name behavior returning figi_candidates, explicit unresolved identifier reporting, and source-labeling of every identifier. No contradiction with annotations exists.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long, but the tool is genuinely complex and nearly every clause earns its place with caveats, examples, and behavioral notes. It is front-loaded with the general purpose and usage directive. The heavy use of nested parentheticals makes it slightly harder to scan, so it is not a perfect 5.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with no output schema, the description thoroughly covers what is returned (CIK, ticker, LEI, FIGI, RxCUI, brand/ingredient, ownership links), when nothing is asserted (figi_candidates), how unresolved identifiers are represented, and how degraded enrichment behaves. An agent has enough context to call this correctly and interpret results.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Although schema coverage is 100%, the description adds substantial meaning beyond the schema: it explains how company values map to ticker/CIK/name/ISIN, gives drug examples, and provides the critical instruction to pass only the entity name, not the full noun phrase, with the reason why. This materially improves correct invocation.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description names a specific verb ('resolve') and resource ('user-spoken NAME to canonical/official identifiers') and states the tool's distinctive role: converting names to the identifiers other tools require. It clearly separates this from sibling tools with phrases like 'Use FIRST whenever you have a name but need an ID' and detailed type/variant examples.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives an explicit trigger condition — 'Use FIRST whenever you have a name but need an ID' — and illustrates the lifecycle with many example phrasings. It does not explicitly name alternative sibling tools and say when NOT to use this one, so it falls just short of the strict 5-level standard.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.6/5.0
Disambiguation1/5

Several tools appear to do the same thing at the top level: ask_pipeworx, ask_pipeworx_beta (explicitly identical today), and ask_pipeworx_grounded are near-duplicate routing entry points, and deep_research overlaps heavily with them. Among the ct_* tools, ct_count_by_condition, ct_competitive_landscape, ct_sponsor_pipeline, and ct_compare_sponsors all provide overlapping counting/landscape functionality, making correct selection genuinely ambiguous.

Naming Consistency4/5

The overwhelming majority of tools use lowercase snake_case and mostly follow a verb_noun or domain-prefixed pattern (ct_search, ct_get_study, list_subscriptions, validate_claim, resolove_entity). Some names are noun phrases rather than verbs (ct_competitive_landscape, entity_profile, polymarket_edge_tracker) but the overall style is consistent and readable, with only minor deviations.

Tool Count2/5

44 tools is far too many for a server named 'Clinicaltrials'; only 13 tools are actually clinical-trials-specific while the rest span general data lookup, prediction markets, memory, subscriptions, and npm scanning. The count is inflated by redundant entry points (ask_pipeworx/beta/grounded) and overlapping ct tools, making the set feel heavy and unfocused.

Completeness4/5

For the clinical-trials registry domain, the surface is largely complete: search, full study details, results summaries, condition counts, sponsor pipelines, location-based lookup, recent updates, and catalyst tracking are all represented. Minor gaps exist (e.g., historical versions/protocol amendments and advanced filter combinations), but most could be worked around via the universal ask_pipeworx router.